EUVIMEDEUVIMED entdecken
EditorialKommentarLeitlinie

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?

Ayesha Shah iD, Gerald Holtmann iD

Alimentary Pharmacology & Therapeutics · 2024-05 · 59 (10) · 1290-1291

DOI: 10.1111/apt.17990 ↗

Kurz gefasst

Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 23.04.2024. Verfasst von Ayesha Shah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Queensland, Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Translational Research Ins…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Inflammatory Bowel Diseases, Anti-Bacterial Agents, Vancomycin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LINKED CONTENT This article is linked to Ricciuto et al paper. To view this article, visit https://doi.org/10.1111/apt.17936

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingInflammatory Bowel DiseasesAnti-Bacterial AgentsVancomycinPractice Guidelines as TopicHumansAdministration, Oral

Substanzen

Anti-Bacterial AgentsVancomycin

Autor:innen und Institutionen

  • Faculty of Medicine, University of Queensland, Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia.

ORCID-Profile: Ayesha Shah, Gerald Holtmann

Zitieren

APA

Shah, A., & Holtmann, G. (2024). Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?. Alimentary Pharmacology & Therapeutics, 59(10), 1290-1291. https://doi.org/10.1111/apt.17990

Vancouver

Shah A, Holtmann G. Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?. Alimentary Pharmacology & Therapeutics. 2024;59(10):1290-1291. doi:10.1111/apt.17990

BibTeX
@article{Shah2024,
  author = {Shah, Ayesha and Holtmann, Gerald},
  title = {Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {10},
  pages = {1290--1291},
  doi = {10.1111/apt.17990}
}
Kostenlos starten →